Since its founding in 2001, LUNGevity has funded **110 research projects** at **57 institutions** in **23 states**, focusing on early detection and more effective treatments of lung cancer.

LUNGevity’s investment in lung cancer research is helping to accelerate advances that are now available for breast, prostate, colorectal, and other cancers — earlier detection, more effective treatment options, higher quality of life, and thousands of lives saved. By finding the disease earlier and treating it more effectively, we can achieve our vision of a world where no one dies of lung cancer.

LUNGevity has a comprehensive approach to pursuing longevity and a higher quality of life for all people affected by lung cancer, not only by funding research into early detection and more effective treatments, but also by offering peer-to-peer support and a robust patient education program. Our programs address all aspects of a patient’s experience and those of their caregivers, friends, and family.
Dear Friends,

When I look back on 2014, I’m struck by the unprecedented speed at which progress is being made for people living with lung cancer. We are experiencing a true sea change in how we approach early detection, treatment, and survivorship for this long-underserved population. Important discoveries in research, combined with faster clinical application, offer new hope and improved survival for patients.

At LUNGevity, we support the lung cancer community by being 100% patient-focused in all we do. Our scientific research program funds studies that have the potential to revolutionize outcomes for those diagnosed with lung cancer. With our strategic approach in two priority areas — finding lung cancer early and treating it more effectively — our research speeds breakthroughs to patients so that people with lung cancer can live longer and better lives.

LUNGevity’s commitment to those living with lung cancer and their caregivers, friends, and family drive our portfolio of education and support programs. Our goal is to empower all people navigating a lung cancer diagnosis by providing easily accessible, accurate, and up-to-date resources.

In 2014, we continued to pursue our goal of improving outcomes for lung cancer patients by funding even more innovative, impactful science. Highly promising projects in early detection include the development of blood tests and nasal biomarkers to detect lung cancer early, improve the accuracy of diagnoses, and determine a person’s risk of developing lung cancer. In targeted therapies, grantees are exploring a potential new target for lung cancer treatment in people with early-stage lung cancer, using the immune system to attack lung cancer cells, and investigating a new drug target to stop the uncontrollable growth of lung cancer.

Our mentored Career Development awardees continue to show excellent progress in their research as well as in their development as independent researchers.

We are also proud this year to have served a growing number of people affected by lung cancer. LUNGevity’s educational and support resources reached thousands dealing with the practical, physical, and emotional issues of a lung cancer diagnosis. With dedicated programs for survivors and caregivers, LUNGevity is truly the go-to organization for the lung cancer community.

Hundreds of participants from across the country attended our HOPE Summits, including new Summits in Ohio and Texas. LUNGevity also sponsored over 80 events in 2014, including our signature Breathe Deep events, which educate thousands of individuals about lung cancer and build a strong community for those affected by the disease.

We look forward to 2015 with renewed optimism and determination, knowing we are part of a dynamic time of advances for people living with lung cancer. We also recognize the amazing contributions of our event participants and volunteers, our corporate sponsors, and our donors. Your contributions allow us to continue our essential work. We thank you for your support and pledge to be diligent stewards of your generous donations. Together, we will create a world where no one dies of lung cancer.

Sincerely,

Andrea Ferris
President and Chairman
Anyone with lungs can get lung cancer. You can be in perfect health, with almost no symptoms, and still be diagnosed with lung cancer. My first oncologist gave me little hope, approximately 9-12 months to live. The second oncologist had a different take. He wanted to send my tissue to be tested for genetic mutations. Four weeks later, I tested ALK-positive.* I began taking a targeted inhibitor drug. My most recent scan shows that the cancer has gone into remission. I remember thinking I looked like a lit-up Christmas tree on those first scans. For now, I feel like I’m a walking miracle.

DAN POWELL
diagnosed 2014, stage IV ALK+ adenocarcinoma

*ALK-positive: Patients who are ALK-positive respond very quickly to the specific drug that targets their mutation. However, for the vast majority of patients, the drugs are only effective for a limited period of time.

WHAT DO A QUARTER, A PEA, AND A MICROSCOPE SLIDE HAVE TO DO WITH SURVIVING LUNG CANCER?

It’s a fact: finding lung cancer earlier translates to more survivors. Currently, most lung cancer tumors are found by conventional X-ray, when they are the size of a quarter. By this stage, the cancer has metastasized and is much more difficult to treat. However, low-dose computed tomography (LDCT) scans are finding tumors when they are the size of a pea, when the cancer is more likely to respond to treatment. The National Lung Screening Trial proved a significant reduction in mortality when lung cancer was found at earlier stages using LDCT. But the high false positive rate of LDCT and the current guidelines that recommend LDCT only for those at highest risk leave a serious deficiency in the early detection of this disease. LUNGevity, the only lung cancer nonprofit with a focus on early detection research, is funding the development of blood- and sputum-based biomarkers to complement LDCT. Our goal is to reverse the current statistics, so that the majority of lung cancers are found in the earliest, most treatable stages.

2014 EARLY DETECTION RESEARCH AWARDS

The Early Detection Awards for Translational Research Program supports new approaches to improve clinical methods for the detection of primary tumors.

IDENTIFYING MUTATIONS THAT INCREASE THE RISK OF DEVELOPING LUNG CANCER

Identifying germline risk mutations for early-onset and familial NSCLC
Zeynep H. Gümüş, PhD
Icahn School of Medicine at Mount Sinai
Steven M. Lipkin, MD, PhD
Joan & Sanford I. Weill Medical College of Cornell University
Kenneth Offit, MD, MPH
Memorial Sloan Kettering Cancer Center
Lung cancer often affects those with no history of smoking, sometimes even young children, suggesting that there may be underlying genes that could predispose one to the disease. This team of researchers plans to identify genes associated with the risk of developing lung cancer. Increased surveillance and testing could then be conducted on people who carry the high-risk genes.

IMPROVING DETECTION OF EARLY-STAGE LUNG CANCER BY BLOOD TESTS

Detection of early-stage lung cancers via tumor DNA in blood
Abhijit Patel, MD, PhD
Yale University
A simple blood test that permits early detection of lung cancer could greatly improve treatment outcomes. Dr. Patel will test whether bits of DNA from lung tumors can be detected in patient blood samples. Since tumor DNA contains many specific genetic alterations, Dr. Patel will examine whether such DNA containing these telltale alterations can be identified in the blood of patients with lung cancer.

DEVELOPING A NASAL TEST FOR EARLY-STAGE LUNG CANCER

Nasal biomarkers for the evaluation of lung nodules found by low-dose CT screening
Kimberly M. Rieger-Christ, PhD
Jacob Sandi, MD
Lahey Hospital & Medical Center
Katrina Stelling, MD, MSc
Boston University
CT screening for lung cancer can improve survival but sometimes identifies indeterminate lung nodules. Though these are often benign, some patients undergo subsequent costly tests and risk complications. A research team from Lahey Hospital & Medical Center and Boston University will test nasal swabs of these patients to develop a biomarker to help distinguish early lung cancers from benign lesions.
Today, we understand that there will be no single cure for lung cancer; it is not just one disease. Lung cancer has multiple recognized variants, each one requiring its own combination of therapies.

Over the past several years, there has been an exciting increase in the understanding of the cellular drivers of lung cancer. This understanding is being driven in part by breakthroughs in technology like next-generation sequencing. In non-small cell lung cancer, molecular biomarkers have been identified in more than half of the cases. New classes of drugs, such as immunotherapies, are also showing great promise and possible application in areas that haven’t seen new advances in many years, such as small cell or squamous cell carcinoma. But matching them with the right patient for maximum effectiveness and minimum side effects remains a challenge. LUNGevity wants to ensure that every patient has the best match for their particular lung cancer, resulting in longer, better-quality lives.
WHAT IF EACH OF US ALREADY HOLDS THE KEY TO CURING LUNG CANCER?

Lung cancer patients are now benefiting from an exciting new line of treatment — immunotherapy — that uses the body’s own immune system to fight the cancer. Specifically, this treatment aims to enhance the body’s immune response and stop the lung cancer from evading the immune system. With patients taking part in the research process by participating in clinical trials, doctors are seeing promising results. Three types of immunotherapies currently being studied in non-small cell lung cancer (NSCLC) include immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapy, with the first showing the most progress at this time. Immunotherapy is also being studied in small cell lung cancer (SCLC), which currently has fewer treatment options.

“After a series of failed chemotherapy and radiation treatments, I was one of 100 people in the world in 2011 to be part of an immunotherapy treatment trial, and my tumor shrank significantly. My hope is that my being part of that trial will lead, someday, to a cure for lung cancer.”

DAVID GOBIN, diagnosed 2008, stage IV squamous cell carcinoma

“LUNGevity is a foundation that really believes in trying to get the latest and greatest treatments to patients as quickly as possible. So they look to fund research that can accelerate the pace of patients getting cutting-edge treatment. One of the most exciting areas in lung cancer right now is immunotherapy. Instead of the treatment actually killing the cancer cells, the goal of the treatment is to stimulate the patient’s own immune system and get the immune system to see and recognize the cancer and go after it.”

LECIA SEQUIST, MD, MPH, Massachusetts General Hospital, LUNGevity Scientific Advisory Board Member

“LUNGevity is funding projects that will accelerate advances in immunotherapy, bringing new hope for lung cancer patients. In addition to the two immunotherapy awards described on page 7, immunotherapy is also allowing exciting collaborations across cancer types. One such collaboration focuses on new treatments for late-stage disease.

2014 IMMUNOTHERAPY RESEARCH AWARD

LUNGevity is funding projects that will accelerate advances in immunotherapy, bringing new hope for lung cancer patients. In addition to the two immunotherapy awards described on page 7, immunotherapy is also allowing exciting collaborations across cancer types. One such collaboration focuses on new treatments for late-stage disease.

Response to PD-1 inhibitors in melanoma and lung cancer patients with brain metastases

Lucia Beatrice Jilaveanu, MD, PhD
Yale University

This grant was co-funded by the Melanoma Research Alliance, LUNGevity Foundation, and the Lung Cancer Research Foundation

Brain metastases are extremely common in both NSCLC and melanoma patients. Two new immunity-boosting drugs are showing promise in both sets of patients. However, whether these drugs work on cancer cells that metastasize and lodge in the brain is not known. Researchers from Yale will study patients with brain metastases treated with the new drugs to find biomarkers that could predict the patients’ response to this treatment.

Lucia Beatrice Jilaveanu, MD, PhD
2014 CAREER DEVELOPMENT AWARDS

LUNGevity’s Career Development Awards Program advances our knowledge of lung cancer while creating opportunities for, and supporting the careers of, talented future leaders who will keep the field vibrant with new ideas.

2014-2017 Career Development Awardees

IMMUNOTHERAPY FOR EARLY-STAGE LUNG CANCER

Newadjuvant anti-PD-1 antibody, nivolumab, in resectable NSCLC

Patrick Forde, MD (MB, BCh)
Johns Hopkins Kimmel Cancer Center

One kind of new cancer treatment works by stimulating the immune system to attack cancer cells. This treatment uses anti-PD-1 antibodies to release the “brakes” on the immune system. Anti-PD-1 has been successful in lung cancer that is resistant to standard chemotherapy. Dr. Forde will test whether this treatment is effective in earlier-stage lung cancer patients.

OVERCOMING DRUG RESISTANCE IN ALK-POSITIVE LUNG CANCER

Dissecting the role of negative feedback inhibition in ALK+ lung cancer

Christine Lovly, MD, PhD
Vanderbilt University School of Medicine

A subset of lung cancer patients have mutations in a gene called ALK. These patients can be successfully treated with ALK inhibitors, but resistance often develops. Dr. Lovly will identify novel molecular targets that can be blocked in combination with ALK inhibitors to overcome resistance and promote better responses.

UNDERSTANDING DRUG RESISTANCE IN SMALL CELL LUNG CANCER

Molecular mechanisms of acquired drug resistance in small cell lung cancer

John Poirier, PhD
Memorial Sloan Kettering Cancer Center

This grant was co-funded by the American Lung Association

Small cell lung cancer is an exceptionally aggressive type of lung cancer. While these tumors are initially responsive to a combination of chemotherapy drugs, tumor recurrence is near universal. Dr. Poirier will develop and study models of drug resistance to identify new strategies to overcome chemotherapy resistance.

2013-2016 Career Development Awardees

Funding for the second year of three-year grants initiated in 2013 was provided in this fiscal year.

Targeting KRAS-mutant NSCLC through inhibition of mTOR and Hsp90

Timothy Burns, MD, PhD
University of Pittsburgh Cancer Institute

Biomarkers for NSCLC radiosensitization by proteasome inhibition

David Kozono, MD, PhD
Dana-Farber Cancer Institute

Biomarkers for targeted lung cancer chemoprevention

Meredith Tennis, PhD
University of Colorado Denver

IN ALK-POSITIVE LUNG CANCER

Resistant in resectable NSCLC

David Gersten School of Medicine at UCLA

Professor and Vice Chair of Research, Radiology

A subset of lung cancer patients have mutations in a gene called ALK. These patients can be successfully treated with ALK inhibitors, but resistance often develops. Dr. Lovly will identify novel molecular targets that can be blocked in combination with ALK inhibitors to overcome resistance and promote better responses.
In 2014, LUNGevity’s Breathe Deep program evolved from a grassroots event network to a comprehensive community engagement program. By engaging individual communities—their citizens, hospitals, businesses and civic groups—we are creating a stronger national movement to change outcomes for people living with lung cancer. In doing so, LUNGevity is not only raising significant funds for research and support programs, but is also raising the national profile of lung cancer, one community at a time.
LUNGevity Special Events Raise Funds and Celebrate the Extraordinary Progress in Lung Cancer Research.

LUNGevity brings together business leaders, philanthropists, survivors, and researchers to celebrate at the Celebration of Hope Gala in New York, the Musical Celebration of Hope Gala in Washington, DC, and the Fall Benefit in Chicago.

1) We are thankful to gala chairs Michelle Olson and Ginny Groom for their dedication to making the 2013 Celebration of Hope Gala a memorable event. 2) Guests at LUNGevity’s galas include survivors and leaders in the fields of business, civic, and philanthropy. 3) David E. Kazeroo, MD, PhD, the recipient of the Melissa Lumbang Zagon Founders Award, is pictured with survivor and long-time LUNGevity volunteer Jill Feldman at the 2013 Fall Benefit in Chicago. 4) The LUNGevity 2013 Musical Celebration of Hope Gala, pictured, featured an Arabian Nights theme. Event emcees like Andrea Roane, WUSA9 broadcast journalist, are often engaging and vivacious local celebrities. 5) Guests raise their glasses to celebrate and toast to another year of hope and promise.

LUNGevity Grassroots, Benefactor, Gala, and Special Events July 1, 2013—June 30, 2014

Arizona
- Breathe Deep Phoenix

California
- Breathe Deep Bay Area—San Jose
- Breathe Deep San Diego
- Paddle for Humanity—Newport Beach

District of Columbia
- Breathe Deep DC
- LUNGevity’s Musical Celebration of Hope Gala
- Paddle for Humanity

Florida
- Breathe Deep Pompano Beach
- Breathe Deep Tampa

Georgia
- Breathe Deep Atlanta
- Breathe Deep Blue Ridge
- Team LUNGevity—Publix Georgia Marathon & Half Marathon—Atlanta

Illinois
- 7th Annual Pauline-Moracco Lung Cancer Walk & Rally—Chicago
- Breathe Deep Busse Woods
- Breathe Deep Central Illinois—Bloomington
- Breathe Deep Chicago Golf Outing—Long Grove
- Breathe Deep Chicago Yogaathon—Highland Park
- Breathe Deep Kankakee
- Breathe Deep Lake Arlington
- Breathe Deep Naperville
- Breathe Deep North Shore—Deerfield
- The John Whiteside/Beatrice Green Lung Cancer Walk & Fun Run—Arlington Heights
- LUNGevity Foundation Annual Fall Benefit—Chicago
- Spare a Life—Strike Out Lung Cancer—Kankakee
- Team LUNGevity—Bank of America Chicago Marathon

Iowa
- Breathe Deep Des Moines

Maryland
- 3x3 Snow Ball Fight Lacrosse Tournament—Frederick
- Breathe Deep Baltimore
- Breathe Deep Columbia
- Suzi Carmassi Golf Classic—Jamison

Massachusetts
- Breathe Deep Boston 5K Walk
- Paddlpalooza—Newton
- Upstage Lung Cancer’s 5th Annual Cabaret Concert—Boston

Michigan
- Breathe Deep Ann Arbor
- Breathe Deep Fashion Show—Birmingham
- Breathe Deep Michigan—Birmingham

Missouri
- The Lung Hill Run—Kansas City

Nationwide
- Be Bold, Be Bald!

New Hampshire
- Breathe Deep New Hampshire—Concord

New Jersey
- Breathe Deep South Jersey—Pennsauken
- Just Breathe Yogathon—Somers Point
- Walk, Run, Survive 5K—Ocean City

New York
- 3-on-3 Basketball Tournament—Rye Brook
- Breathe Deep Albany
- Breathe Deep CNY—Liverpool
- Breathe Deep NYC
- Kickstart Your Lungs—Clay
- LUNGevity’s Celebration of Hope Gala—NYC
- Team Labrecque—LUNGevity—NYC Half Marathon
- Team Labrecque—LUNGevity—Run As One—NYC
- Team Labrecque—LUNGevity—Run As One ING New York Marathon—NYC

North Carolina
- Breathe Deep Cary Golf Classic

Ohio
- Breathe Deep Columbus
- Breathe Deep Nework
- Ohio HOPE Summit—Columbus

Pennsylvania
- Breathe Deep NE Pennsylvania—Kingston
- Breathe Deep Philadelphia

Tennessee
- Breathe Deep Nashville Stache and Lash 5K

Texas
- Breathe Deep DFW
- Dallas HOPE Summit
- Paddle for Humanity—Austin
- Third Annual Golf Tournament in Memory of Florence Blackwell—Austin

Utah
- Breathe Deep Salt Lake City

Virginia
- 3rd National HOPE Summit—Arlington
- 6th Annual Beth Whitaacre Golf Tournament—Lorton
- Breathe Deep DC Golf Classic—Arlington

Washington
- Breathe Deep Seattle
- Lung Cancer Awareness and Fundraising Reception at glassybaby—Seattle
- Paddle for Humanity—Seattle

EVENTS COAST TO COAST

We are grateful to all of our participants and supporters. These events have the shared goals of increasing awareness of the urgent need for earlier detection and improved treatment of lung cancer and raising critical funds for research and programs to change patient outcomes. More than 25,000 people participated in LUNGevity events this year.
LUNGEVITY IS COMMITTED TO BUILDING A COMMUNITY OF SUPPORT AND HOPE FOR THOSE AFFECTED BY LUNG CANCER.

Through our online peer-to-peer support and in-person survivorship programs, LUNGevity connects, educates, and empowers survivors and caregivers. This year, we continued to develop important patient resources and to address the unmet needs of people navigating a lung cancer diagnosis.

Providing positive support and up-to-date, accurate resources to survivors is a key tenet of our mission to increase quality of life and survivorship for people living with lung cancer.

PEER-TO-PER support
Sustaining a Powerful LifeLine
Through our LifeLine Program, we continue to offer one-on-one phone and email support by matching patients and caregivers with mentors who have undergone similar experiences.

LUNGEvity Lung Cancer Support Community
The LUNGEvity Lung Cancer Support Community (LCSC), the largest online lung cancer support network, has over 400,000 posts addressing the latest lung cancer information and alerts about lung cancer events and advocacy opportunities. Patients, survivors, and others share their personal experiences and provide support for each other.

Engaging People through Social Media
LUNGEvity’s social media community is strong and growing. With more followers, and increased interaction, we’re sharing our message with tens of thousands of interested supporters. Our social media platforms help supporters and advocates connect with each other and change how people learn about, treat, and live with lung cancer.

IN-PERSON SURVIVORSHIP PROGRAMS
LUNGEvity’s HOPE Summits provide an opportunity for survivors and caregivers to come together in a supportive and educational environment. Attendees learn about advances in research and treatment, developments in health and nutrition, improving communications with caregivers and medical professionals, and finding a creative outlet for sharing their story. The summits feature inspirational speakers, medical expert forums, and opportunities for lung cancer survivors to connect with other survivors.

The program continues to grow in attendance and impact. New regional HOPE Summits were held in Ohio and Dallas, and the fourth annual National HOPE Summit was held in Washington, DC, in May.

2014 MARKED LUNGEVITY’S FIRST REGIONAL HOPE SUMMIT AND THE FOURTH ANNUAL NATIONAL HOPE SUMMIT.

1) HOPE Summits create an opportunity for survivors like Ole Pertet and Randy Broad to connect with others who have or have had lung cancer. 2) Survivors and caregivers can attend interactive, expert-led sessions. 3) Cynthia Cooke and her mother, Barbara Culbertson, are reunited with Katie Brown, LUNGEvity’s Vice President for Support and Survivorship Programs. Participants who have been to a Summit report feeling a sense of community and have built lasting friendships. 4) Speakers give informative and exciting presentations about the latest in research and treatment options. 5) Phillip Moore III stands in front of Georgetown University. The National HOPE Summit is held each May in Washington, DC. 6) Matt Ellefson shares his compelling story during one of the workshops. The Summit also holds peer-to-peer sessions where attendees can hear directly from other lung cancer survivors who have taken the journey. 7) Survivors and friends Nelise Vinogradoff, Joyce Shih, and Frances Beard inspired each other to remain determined and optimistic. 8) Survivors who attend HOPE Summits can learn how to live, survive, and thrive after a lung cancer diagnosis.
DONORS

The generous support from our friends allows LUNGevity to fund cutting-edge translational research and to offer information, support, and most important, hope to lung cancer survivors and their families.

BEACONS OF HOPE

Individual, Corporate, and Organizational Gifts of $5000 and above

Abbott Molecular
Karim and Daniel Akerson
Alfred & Lotte Guze Foundation
American Lung Association
Ashbel Family Charitable Foundation
Arnold & Porter LLP
Shelby Cavanah
Allison Cascone
Elizabeth Burkhard
Fran Bruno-McBreen
Katie Brown
Adrian Breckel
Michele Bowles
Gina Bono
McGraw-Hill Education & Research Foundation
Mindshare
Wendy Conrad and Neal Aronson
Corporate Executive Board
Crane Fund for Widows and Children
Jim Dandy
Gayle and Daniel D’Arienzo
Diageo North America Foundation
The Dow Chemical Company
Amanda and Jonathan Eldin
EM3 Senro, Inc.
Estee Lauder Companies
Dalia and Hossein Fatemi
The Fernandez Foundation
Forbes Partners and Building Materials Corp.
Andrea and George Ferris
Honorable Barbara Hackman Franklin and Mr. Wallace Barnes Genentech
Claudette and Jackie Gersten
Gibson, Dunn & Crutcher LLP
Carol and David Gichner
Kilpatrick Townsend
Sklooton LLP
Knowledge V
Dana and Michael Landow,
Dulles Jet Center
Susan and David Landrow,
Dulles Jet Center
Leonard Lauder
The Lauder Foundation
Elise and Marc Lefkowitz
Life Technologies
Lilly Oncology
The Honorable Frederic V. Malek and Mrs. Malek
Marian and Edward Saltzberg Foundation
The Marion and Robert Rosenthal Family Foundation
Hematology-Oncology Associates of CHF, PC
Helen Lee Henderson
Lisa Henkoff and Manu Rana
Heritage Title Company of Austin, Inc.
Rena and Scott Hoffman
International Franchise Association
Interstate Management Inc.
JAB Produce, Inc.
Kenneth M. Jacobs
Lori Jagoda
Carol and Joel Jankowski
Janssen
Jens Day
Keiko and Stephen Kaplan
Katten, Muchin, Rosenman LLP
Kim and Loren Katzovitz
Sheryl and Charles Kaye
KICIC
Bobbie and Bill Kilberg
KCIC
Linda and Edwin Phelps
KPMG
Patti and Mark Ranton
Marion and Robert Rosenthal
Royalty Pharma
Saundi Aramco
Rebekah and Iman Shalit
Shook, Hardy & Bacon LLP
Sidney Austin LLP
Laura and Mark Urken
Sleiman Family
The Star Foundation
Sara Stewart
Constance Milstein de Cabral
Lila Hays St. Hilaire
Dr. John and Susan Stivison
TDC Boosters
Tea Neuroscience
The Thomas G. LaBrecque Foundation
Tick Tock Productions, Inc.
Torque Foundations
Lamont J. du Pont
Amiee S. Tolal
TTR Sotheby’s
International Realty
Martha Updike
Upstate Lung Cancer Association
Laura Oto
Michelle and Chris Olson
Pennisius Private Wealth Management
Ginger and Stuart Pape
Sue and Bob Pence
Pfizer Inc.
Linda and Edwin Philips
Philip A. Hadley Foundation
Janet K. Phillips
Fiduciary
PPL Group LLC
Blair and Stephen Raber
The Randy Cappello Foundation
Relax The Back Corporation
Pattie Papanicolaou
Sandra Anderson and Joe Vaccarella
Rick Angel
Peter Angus
Tracy and Howard Arkin
Procilla Annamathodu
Colleen Ann}
Ann and Matthew Anthony
Melissa Apal and Tony Modelfilo
Jonathan D. Appelbaum
Harleen Appelgate
Applebee’s
Arbella Insurance Group
AFCO/Murray National Construction Company, Inc.
Angela Ardisic
Diane and Thomas Arenberg
Ashley Adams
Jessica Adler
Melissa Allen
Karen and Frank Allen
Mary Anderson
Daniel Anderson
American Radiology
Assured Guaranty
Jane and Norm Alpert
Nancy and Joel Altobello
American Endowment Foundation
American Lung Association
American Red Cross
Albany Medical Center
AMLI Residential
Patti Papanicolaou
Sandra Anderson and Joe Vaccarella
Rick Angel
Peter Angus
Tracy and Howard Arkin
Procilla Annamathodu
Colleen Ann
Ann and Matthew Anthony
Melissa Apal and Tony Modelfilo
Jonathan D. Appelbaum
Harleen Appelgate
Applebee’s
Arbella Insurance Group
AFCO/Murray National Construction Company, Inc.
Angela Ardisic
Diane and Thomas Arenberg
}
2014 Annual Report

Evity Foundation
Lung 2014 Annual Report
LUNGevity Foundation remained fiscally strong in FY 2014, thanks to a diverse set of donors. We were able to continue to grow our programs while adding online and offline support resources and new national events, increasing the population we serve.

The financial activities of LUNGevity Foundation were audited by Ostrow, Reisin Berk & Abrams, Ltd. For our complete audited financial statements, please visit our website at www.LUNGevity.org.

2014 TOTAL REVENUE: $6,817,044
2014 TOTAL PROGRAM EXPENSES: $4,207,916
**SUMMARY OF PROFIT AND LOSS**

*June 30, 2014*

**2014**

<table>
<thead>
<tr>
<th>Revenues:</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and grants</td>
<td>$2,633,539</td>
</tr>
<tr>
<td>Special events and other fundraisers</td>
<td>3,923,119</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>1,043</td>
</tr>
<tr>
<td>Donated goods and services</td>
<td>259,343</td>
</tr>
<tr>
<td>Total revenue</td>
<td>$6,817,044</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses:</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>$4,207,916</td>
</tr>
<tr>
<td>Management and general</td>
<td>681,192</td>
</tr>
<tr>
<td>Fundraising</td>
<td>772,390</td>
</tr>
<tr>
<td>Special events</td>
<td>1,094,332</td>
</tr>
<tr>
<td>Net realized loss on investments</td>
<td>6,381</td>
</tr>
<tr>
<td>Loss on dispersal of assets</td>
<td>2,787</td>
</tr>
<tr>
<td>Total expenses</td>
<td>6,764,998</td>
</tr>
</tbody>
</table>

| Change in net assets       | 52,046          |

**Net assets:              **

| Beginning of year | 3,011,096 |
| End of year       | 3,063,142 |

**STATEMENT OF FINANCIAL POSITION**

*June 30, 2014*

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$3,455,436</td>
<td>$3,104,843</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>206,010</td>
<td>201,731</td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>1,120,000</td>
<td>638,302</td>
</tr>
<tr>
<td>Pledges receivable</td>
<td>656,982</td>
<td>671,398</td>
</tr>
<tr>
<td>Security deposits</td>
<td>14,752</td>
<td>9,722</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>31,761</td>
<td>34,898</td>
</tr>
<tr>
<td>Total assets</td>
<td>$5,484,941</td>
<td>$4,660,894</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$24,749</td>
<td>$31,660</td>
</tr>
<tr>
<td>Accrued payroll and vacation liabilities</td>
<td>32,888</td>
<td>91,702</td>
</tr>
<tr>
<td>Grants payable</td>
<td>2,353,689</td>
<td>1,507,206</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>10,473</td>
<td>19,230</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>2,421,799</td>
<td>1,649,798</td>
</tr>
</tbody>
</table>

| Net assets:                 |                 |                 |
| Unrestricted                | 2,046,160       | 2,339,698       |
| Temporarily restricted      | 656,982         | 671,398         |
| Total net assets            | 3,063,142       | 3,011,096       |
| Total liabilities and net assets | $5,484,941 | $4,660,894     |
WE THANK YOU FOR YOUR CONTINUED SUPPORT AND HOPE YOU WILL JOIN US IN 2015!

LUNGevity is committed to changing outcomes for people living with lung cancer by accelerating research, strategically growing our programs, and forging meaningful collaborations in the lung cancer community. Through the involvement and investment of our donors and volunteers, we were able to make great progress in 2014.

GET CONNECTED

If you or a loved one is a lung cancer patient, LUNGevity offers many resources for you to connect with other survivors, caregivers, and advocates, including the Lung Cancer Support Community online support network, the LifeLine Support Partner program, our Survivor Resource Center, and our Caregiver Resource Center.

Follow us on social media to get the latest news about LUNGevity and our partnerships.

- facebook.com/LUNGevity
- twitter.com/LUNGevity
- youtube.com/LUNGevity
- instagram.com/LUNGevity
- pinterest.com/LUNGevity

GET ENGAGED

Participate in a Breathe Deep Event or Create Your Own

Come together with your community to celebrate survivors, learn about progress being made, and remember loved ones. Volunteer, join in, or create your own unique event!

Attend a Celebration of Hope Gala or Benefit

Our premier events bring together leaders in the fields of business, civics, and philanthropy for a night of celebration and inspiration. We hope you will join us for these beautiful and meaningful evenings and support our work on behalf of the lung cancer community.

Go the Distance with Team LUNGevity

Join the dedicated athletes of Team LUNGevity who are running, walking, biking, and swimming in endurance events across the country to help bring an end to lung cancer!

SAVE LIVES

This is an unprecedented time of progress and promise for lung cancer research. By donating today, you can help create a world where people live longer and live better with lung cancer.